2099719-47-6

2099719-47-6 structure
2099719-47-6 structure
  • Name: Betrixaban hydrochloride
  • Chemical Name: Betrixaban hydrochloride
  • CAS Number: 2099719-47-6
  • Molecular Formula: C23H23Cl2N5O3
  • Molecular Weight: 488.37
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease Factor Xa
  • Create Date: 2022-08-15 12:00:41
  • Modify Date: 2025-08-25 14:12:47
  • Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect[1][3].

Name Betrixaban hydrochloride
Description Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect[1][3].
Related Catalog
Target

IC50: 1.5 nM (fXa)[1] Ki: 0.117 nM (fXa), 1.8 μM (hERG)[1]

In Vitro Betrixaban (PRT054021) shows IC50 of 8.9 μM in patch clamp hERG assays[1]. Betrixaban shows an IC50 and a Ki of 6.3 μM and 3.5 μM for the plasma kallikrein, respectively[1]. Betrixaban (hERG Ki 1.8 μM) exhibits significantly lower hERG activity than all the others (hERG Ki⩽0.5 μM)[1]. Betrixaban (5-25 ng/mL) inhibits thrombin generation[3].
In Vivo Betrixaban (0.5 mg/kg, i.v.; 2.5 mg/kg, p.o.) has bioavailability of 51.6% in dog[1]. Betrixaban (0.75 mg/kg, i.v.; 7.5 mg/kg, p.o.) has bioavailability of 58.7% in monkey[1]. Betrixaban mediated whole-blood INR increase is reversed by r-Antidote. After i.v. infusion for 30 min, the total plasma concentrations of Betrixaban is 0.2±0.01 μM, and the percentages of unbound inhibitor is 40%±7.2%. After administration of r-Antidote, the total plasma concentration increased to 2.0±0.4 μM, and the percentage of unbound inhibitor declined to 0.3%±0.1%[2]. Betrixaban (3 mg/kg) shows nearly comparable inhibition of thrombus mass to enoxaparin 1.6 mg/kg (76% vs 96% inhibition) in the rabbit abdominal vena cava model of clot accretion on cotton threads[3]. Betrixaban (19.1 mg/kg) is at least as effective at maintaining patency as enoxaparin 7.6 mg/kg and clopidogrel 3 mg/kg/d (90% vs 70% vs 80% patency, respectively) in the ferric chloride injury model of rodent carotid artery[3].
References

[1]. Zhang P, et al. Discovery of Betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19(8):21

[2]. Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 Apr;19(4):446-51.

[3]. Chan NC, et al. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.

Molecular Formula C23H23Cl2N5O3
Molecular Weight 488.37
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.